Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks-Reference-Cited by-同舟云学术

Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks

Published:2024-01-03 Issue:6 Volume:30 Page:1076-1078
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Silk Ann W.¹^ORCID,Davar Diwakar²³^ORCID

Affiliation:

1. 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

2. 2University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania.

3. 3University of Pittsburgh, Pittsburgh, Pennsylvania.

Abstract

Summary A recent report sheds light on the tumor-associated macrophages (TAM) in Merkel cell carcinoma (MCC), and the association of S100A8-expressing TAMs with resistance to anti–PD-(L)1 inhibitors. These data improve our understanding about why some tumors with brisk tumor-infiltrating lymphocytes do not respond to immunotherapy and provide a compelling rationale to target myeloid checkpoints in MCC. See related article by Tabachnick-Cherny et al., p. 1189

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-3320/3398125/ccr-23-3320.pdf

Reference20 articles.

1. Characterization of immunosuppressive myeloid cells in Merkel cell carcinoma: correlation with resistance to PD-1 pathway blockade;Tabachnick-Cherny;Clin Cancer Res,2024

2. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma;Starrett;Genome Med,2020

3. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities;Harms;Nat Rev Clin Oncol,2018

4. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial;D'Angelo;JAMA Oncol,2018

5. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy;Nghiem;J Clin Oncol,2019